Abstract
Purpose: The use of highly purified follicle-stimulating hormone (Metrodin-HP) was compared with that of a preparation containing follicle-stimulating hormone and luteinizing hormone (Pergonal) for production of superovulation in an IVF program.
Methods: We used the Oxford Fertility Unit database to identify patients undergoing their first cycle of IVF, using either Metrodin-HP or Pergonal. Patients were treated with a standardized drug protocol and were stratified by age and cause of infertility. Ovarian stimulation with either Metrodin-HP (Serono Laboratories) or human menopausal gonadotropin (hMG; Pergonal; Serono Laboratories) after pituitary desensitization commenced in the midluteal phase of the preceding cycle. Monitoring was performed by ultrasound and serum estradiol measurement prior to transvaginal oocyte recovery, followed by IVF and transfer of no more than three embryos.
Results: For Metrodin-HP versus Pergonal, the rates of egg retrieval (98 vs 94%), fertilization (89 vs 92%), clinical pregnancy (32.9 vs 23.4%), miscarriage (4.1 vs 4.5%), live birth (26 vs 18.5%), and ovarian hyperstimulation syndrome (5.5% vs 5.9%) were similar in both groups. The apparent increase in clinical pregnancy and live birth with Metrodin-HP did not reach statistical significance. The dosages of gonadotropins used were comparable. Estradiol levels measured on day 8 of stimulation were significantly lower in the Metrodin-HP group than in the Pergonal group, but the difference did not reach statistical significance on the day of hCG administration. Significantly more follicles (greater than 12 mm) were obtained in the Metrodin-HP group, but the numbers of eggs recovered and fertilized were similar in the two groups.
Conclusions: These findings demonstrate that highly purified FSH (Metrodin-HP) is as effective and successful as hMG (Pergonal) for ovarian stimulation in a standard IVF regimen. Exogenous luteinizing hormone (LH) is not required for satisfactory ovarian stimulation in IVF. Measurement of estradiol may be less helpful in the monitoring of Metrodin-HP cycles, but the level reached on the day of hCG administration can still be used to predict, and hence avoid, ovarian hyperstimulation syndrome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Couzinet B, Lestrat N, Brailly S, Forest M, Schaison G: Stimulation of ovarian follicular maturation with pure follicle-stimulating hormone in women with gonadotrophin deficiency. J Clin Endocrinol Metab 1988;66:552–556
Shaw RW, Ndkwe G, Imoedemhe DA, Bernard AG, Burford G: Twin pregnancy after pituitary desensitization with LHRH agonist and pure FSH. Lancet 1985;2:506
Hughes EG, Ferdorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA: The routine use of gonadotrophin-releasing hormone agonists prior to in vitro fertilization and gamete intra fallopian transfer. A meta-analysis of randomised controlled trials. Fertil Steril 1992;58:888–896
Bergh C, Olsson JH, Selleskog U, Hillensjo T: Steroid production in cultured thecal cells obtained from human ovarian follicles. Hum Reprod 1993;8:519–524
Homburg R, Armar NA, Eshel A, Adams J, Jacobs HS: Influence of serum luteinizing hormone concentrations on ovulation, conception and early pregnancy loss in polycystic ovary syndrome. BMJ 1988;297:1024–1026
Regan L, Owen EJ, Jacobs HS: Hypersecretion of luteinising hormone, infertility and miscarriage. Lancet 1990;336:1141–1144
Le Cottonec JY, Porchet HC, Beltrami V, Howles C: Comparative pharmacokinetics of two urinary human follicle stimulating hormone preparations in healthy female and male volunteers. Hum Reprod 1993;8:1604–1611
Forman RG, Frydman R, Egan D, Ross C, Barlow DH: Severe ovarian hyperstimulation syndrome using agonists of gonadotrophin-releasing hormone for in vitro fertilization. A European series and a proposal for prevention. Fertil Steril 1990;53:502–509
Wikland M, Borg J, Hamberger L, Salander P: Simplification of IVF: Minimal monitoring and the use of subcutaneous highly purified FSH administration for ovulation induction. Hum Reprod 1994;9:1430–1436
Wikland M, Nilsson L, Bergh C, Hamberger L: Results from in vitro fertilisation and intracytoplasmic sperm injection with purified gonadotrophins (Metrodin HP). Hormone Res 1995;43:238–240
Hull MGR, Joels LA, Prosser CJ, Ashcroft SA: Experience using preparations of follicle stimulating hormone alone to stimulate the ovaries for assisted conception after pituitary desensitization and simplified management of treatment. Hormone Res 1995;43:230–237
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bagratee, J.S., Lockwood, G., López Bernal, A. et al. Comparison of highly purified FSH (Metrodin-High Purity) with Pergonal for IVF superovulation. J Assist Reprod Genet 15, 65–69 (1998). https://doi.org/10.1007/BF02766827
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02766827